Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company, is set to present at the MicroCap Rodeo Windy City Roundup 2022 on October 12 at 11:00 a.m. ET. CEO Panna Sharma will lead the presentation, which will be live-streamed and available for replay. Lantern Pharma leverages its proprietary RADR® platform for oncology drug discovery, focusing on developing targeted therapeutics based on patient genomic profiles. Attendees can schedule one-on-one meetings with the management team throughout the event.
Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present preclinical data on its drug candidate LP-284 for mantle cell lymphoma (MCL) at the SOHO Tenth Annual Meeting from Sept. 28 to Oct. 1, 2022. LP-284 has demonstrated strong anti-tumor potency in MCL and other non-Hodgkin's lymphomas, particularly against Ibrutinib and Bortezomib-resistant cell lines. The company plans to submit an IND for LP-284 in Q1 2023 and launch a Phase 1 clinical trial in Q2 2023, aiming to capitalize on a $200 million annual market.
Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader webinar on September 22, 2022, at 12:00 p.m. ET. The webinar will address challenges in drug development for pediatric cancers and feature Dr. Peter Houghton, an expert from Greehey Children's Cancer Research Institute. He will discuss disparities in pediatric cancer research and present preliminary results for drug candidates LP-184 and LP-284. Registration details are available, with a replay on Lantern's website from September 23, 2022.
Lantern Pharma Inc. (NASDAQ: LTRN) announced the presentation of positive preclinical data for its drug candidate LP-184 targeting pancreatic cancer at the AACR Special Conference from
Lantern Pharma Inc. (NASDAQ: LTRN) announces that CEO Panna Sharma will present at H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. Lantern Pharma utilizes its RADR® AI platform to enhance oncology drug discovery, focusing on genomically targeted therapeutics. The company is currently developing four drug candidates across nine tumor targets. Details on registration and webcasting are provided for interested investors.
Lantern Pharma Inc. (NASDAQ:LTRN) will feature in an interview on The RedChip Money Report on Bloomberg TV on August 20 at 7 p.m. ET. CEO Panna Sharma will discuss the company's RADR® platform, which uses AI to optimize oncology drug development, aiming to reduce costs and enhance efficiency. Lantern is developing four drug candidates across nine tumor targets, including two in phase 2 trials. The interview is expected to highlight strategic collaborations with esteemed institutions like Johns Hopkins and Fox Chase Cancer Center.
Lantern Pharma (NASDAQ: LTRN) has launched the Phase 2 clinical trial, Harmonic™, for LP-300 targeting never smokers with advanced NSCLC, beginning patient enrollment in Q3 2022. The company plans to submit IND applications for LP-184 and LP-284 in early 2023, with two Phase 1 trials for LP-184 and one for LP-284 expected to commence thereafter. Lantern reported cash holdings of $62.2 million as of June 30, 2022, despite a net loss of approximately $4.5 million for the quarter. The RADR® platform surpassed 21 billion data points, enhancing its capabilities for future partnerships.
Lantern Pharma (NASDAQ: LTRN) will host a webcast on August 8, 2022, at 4:30 PM ET to discuss its Q2 financial results and future milestones. The company, focused on oncology drug discovery using its proprietary RADR® AI platform, is developing four drug candidates and an ADC program. Lantern aims to identify patients likely to respond to its therapies. Panna Sharma, CEO, will lead the discussion. A replay will be available on their investor relations website.
Lantern Pharma (NASDAQ: LTRN) has received FDA clearance to initiate the Harmonic™ trial, a Phase 2 clinical study for LP-300 in never smokers with advanced non-small cell lung cancer (NSCLC). The trial will enroll 90 patients and evaluate the drug in combination with chemotherapy, building on previous successes where LP-300 demonstrated a 91% overall survival and a 125% two-year survival for this demographic. Enrollment is expected to start in Q3 2022, targeting an estimated market of $1.5 to $2 billion for NSCLC.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
